PIK3CB and non-small cell lung carcinoma: In addition, we demonstrated that the gain of PIK3CA mutation may lead to less sensitivity and even resistance to gefitinib in EGFR mutation NSCLC cell lines, due to its activation of PI3K/AKT signal pathway.